Review Article - Journal of Medical Oncology and Therapeutics (2018) Volume 3, Issue 1
MHC class II restricted neoepitope vaccine: Promising strategy for immunotherapy.
The discovery of neoantigens has provided a promising target of cancer immunotherapy. Compared with MHC class II neoantigens, more lights shed on MHC class I neoantigens mediated cytotoxic CD8+ T cell responses. However, recent studies demonstrated that cancer vaccines induce both CD4+ T cell and CD8+ T cell immune responses can enhance anticancer efficacy, which provide a rationale for future cancer vaccine development based on MHC calss II neoantigens.Author(s): Qin Wang, Fangjun Chen, Ju Yang, Baorui Liu